Read More Pharma Industry News Scancell Holdings (LSE:SCLP): Can a Nasdaq deal fund its pivotal melanoma trial? Scancell has strong melanoma data, but Phase 3 still needs funding. A Nasdaq deal could reset LSE:SCLP, or leave investors facing dilution and deal risk. bySrinathJuly 10, 2026